Magazine Article | June 1, 2018

Companies To Watch: Sensorion

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Addressing vertigo and hearing loss inside the inner ear.

SNAPSHOT
Sensorion is a public company in France developing new medicines for diseases of the inner ear, with two compounds in the pipeline: SENS- 111 for treating acute unilateral vestibulopathy (intense vertigo), and SENS-401 for treating hearing disorders such as sudden sensorineural hearing loss (SSNHL) and preventing others such as cisplatin-induced ototoxicity. Now in a Phase 2 trial, SENS-111 is a first-in-class, histamine H4 receptor antagonist. Entering Phase 2 development for SSNHL, SENS-401 is a 5-HT3 receptor antagonist with calcineurin inhibition mode of action.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: